Global Helicobacter Pylori Diagnostics Market 2017-2021
About Helicobacter Pylori Diagnostics
Helicobacter pylori (H. pylori) is gram-negative, aerobic bacteria mostly found in the stomach. The bacterium plays an essential role in maintaining the stomach ecology. H. pylori infection is caused when spiral-shaped bacteria attacks the stomach lining. The bacterium is associated with gastritis and gastric ulcers. It is also linked to stomach cancer and duodenal ulcers. Most of the H. pylori infections are harmless, but these bacteria are also responsible for most of the stomach ulcers and small intestine infections.
Technavio’s analysts forecast the global helicobacter pylori diagnostics market to grow at a CAGR of 8.23% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global helicobacter pylori diagnostics market for 2017-2021. To calculate the market size, the report considers new installations, sales, volume, and value of H. pylori diagnostics market.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Helicobacter Pylori Diagnostics Market 2017-2021
Technavio recognizes the following companies as the key players in the global helicobacter pylori diagnostics market: Thermo Fisher Scientific, Bio-Rad Laboratories, and F. Hoffmann-La Roche.
Other Prominent Vendors in the market are: Alpha Laboratories, Biohit, BIORON Diagnostics, Certest Biotec, Coris BioConcept, Diagnostic Automation/Cortez Diagnostics, Epitope Diagnostics, Exalenz Bioscience, ImevaX, Labsystems Diagnostics, Medline Industries, Meridian Bioscience, Mobidiag, MP Biomedicals, Omega Diagnostics Group, Quest Diagnostics, Quidel, and R-Biopharm.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is higher adoption rate of POC tests. POC test is one of the clinical diagnostics trending high in the H. pylori diagnostics and IVD markets. It provides faster results in non-laboratory settings to support more patient-centered approaches to healthcare delivery. The sensory technology enables rapid analysis of blood samples.”
According to the report, one driver in the market is rising prevalence of disease. According to the CDC, peptic ulcer affects at least one out of ten Americans at some point in their lifetime. Ulcers can cause approximately more than one million hospitalizations and 6,500 deaths annually. The CDC also estimates that the total healthcare cost associated with peptic ulcer in the US to be nearly $6 billion, out of which $3 billion is the hospitalization cost, $2 billion is spent on doctor's office visits, and $1 billion is expected to incur due to decreased productivity and days lost from work.
Further, the report states that one challenge in the market is competitive pricing pressure. The market is highly competitive with the presence of a few established vendors, and many new and small companies. Global vendors invest significantly in marketing, promotion, and improvement of their brand quality to gain profit margins. However, the intense competition in the market leads to a price war. This causes global vendors to lower the average selling price of their devices to compete with high volume and low-cost sales agreement. Vendors also offer discounts, which further contribute to market competition.
hermo Fisher Scientific, Bio-Rad Laboratories, F. Hoffmann-La Roche, Alpha Laboratories, Biohit, BIORON Diagnostics, Certest Biotec, Coris BioConcept, Diagnostic Automation/Cortez Diagnostics, Epitope Diagnostics, Exalenz Bioscience, ImevaX, Labsystems Diagnostics, Medline Industries, Meridian Bioscience, Mobidiag, MP Biomedicals, Omega Diagnostics Group, Quest Diagnostics, Quidel, and R-Biopharm.